Propofol
پروپوفول
🧠 Nervous SystemIV general anaesthetic
Market / country: 🇺🇸 USA
Diprivan (US)
🧮 Dose calculator
General anaesthesia and premedication (adjunct) · Regimen source: FDA Diprivan · 2.7, Table 1FDA Diprivan · 2.2
- • Only by persons trained in anaesthesia, with airway management, oxygen and resuscitation available. FDA Diprivan · 2.1
- • Elderly, debilitated or ASA III/IV: 1–1.5 mg/kg; cardiac: 0.5–1.5; neurosurgical: 1–2 mg/kg. No rapid boluses in the elderly. FDA Diprivan · 2.7, Table 1
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to propofol or its components; history of anaphylaxis to eggs or soy. FDA Diprivan · 4
Warnings
- • Hypotension and respiratory depression; propofol infusion syndrome with high-dose prolonged use; lipid emulsion — strict asepsis (supports microbial growth). FDA Diprivan · 5
Formulations
- 10 mg/mL emulsion (10, 20, 50, 100 mL vials) — injection 🇺🇸 USA FDA Diprivan · 3
- 10 mg/mL emulsion = 10,000 mcg/mL (for infusion rate) — injection 🇺🇸 USA FDA Diprivan · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Diprivan · 8.1
“Risk Summary Data from randomized controlled trials, cohort studies and case series over several decades with propofol use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Diprivan · 8.2
“Risk Summary Based on data from published studies, propofol is present in human milk.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Diprivan · 8.4
“The safety and effectiveness of DIPRIVAN have been established for induction of anesthesia in pediatric patients aged 3 years and older and for the maintenance of anesthesia aged 2 months and older.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Diprivan · 8.5
“The effect of age on induction dose requirements for propofol was assessed in an open-label study involving 211 unpremedicated patients with approximately 30 patients in each decade between the ages of 16 and 80.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA019627
- DailyMed (FDA label)FDA Diprivan
- MedlinePlus (NIH)Propofol Injection
- WHO ATC/DDDN01AX10
- Darooyab (Iran)Propofol
🇮🇷 Registered in Iran Darooyab · G-2676/Propofol
Dosage forms with Iranian generic codes, per Darooyab.
- 01952 · PROPOFOL 1000MG/100ML VIAL · ویال پروپوفول ۱۰۰۰ میلیگرم / ۱۰۰ میلیلیتر
- 16873 · PROPOFOL 2% 50ML VIAL · ویال پروپوفول ۲ درصد ۵۰ میلیلیتر
- 18940 · PROPOFOL 200MG/20ML AMP. · آمپول پروپوفول ۲۰۰ میلیگرم / ۲۰ میلیلیتر .
- 01653 · PROPOFOL 200MG/20ML VIAL · ویال پروپوفول ۲۰۰ میلیگرم / ۲۰ میلیلیتر
- 01951 · PROPOFOL 500MG/50ML VIAL · ویال پروپوفول ۵۰۰ میلیگرم / ۵۰ میلیلیتر
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Diprivan · 3FDA Diprivan · 2.7, Table 1FDA Diprivan · 2.2FDA Diprivan · 2.1FDA Diprivan · 2.7FDA Diprivan · 2.4FDA Diprivan · 2.6FDA Diprivan · 4FDA Diprivan · 5FDA Diprivan · SPL approval / marketing categoryFDA Diprivan · 8.1FDA Diprivan · 8.2FDA Diprivan · 8.4FDA Diprivan · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-2676/Propofol
- Clinical review⚠ Unverified